Senior Director of Business Development, Beam Therapeutics
Sylvia Eash is the Senior Director of Business Development at Beam Therapeutics, a clinical-stage gene editing platform company which is advancing a diversified portfolio of base editing programs. As a senior member of a dynamic BD team, Sylvia has negotiated strategic partnerships with industry leaders such as Apellis, Pfizer, and Lilly, focusing on research collaborations, co-development & co-commercialization options, and licenses. She also oversaw the collaboration with Verve Therapeutics and managed the relationships with Beam’s foundational licensors, including Harvard, Broad, and Editas.
Before joining Beam, Sylvia held director positions in R&D Transactions at Sanofi and in Business Development & Strategic Alliances at Visterra Inc. At Sanofi, she led the licensing agreements for the iAward Program, an initiative aimed at enriching the company’s early-stage pipeline. At Visterra, she negotiated and managed key partnerships, including with Vir Biotechnology.
Earlier in her career, Sylvia served as a Senior Licensing Manager at Mass General Brigham Innovation, where she led BD activities for a high-value IP portfolio, including the establishment of CoStim Pharmaceuticals, later acquired by Novartis. She began her professional journey as a Senior Biopharmaceutical Industry Analyst at Decision Resources.
Sylvia holds a Ph.D. in Pathobiology from Brown University and is passionate about advancing partnerships for therapies that have the potential to transform patient lives.